Precocious puberty: auxological criteria discriminating different forms.
It may be possible to recognize different forms of precocious puberty at the first evaluation. In a group of 26 sexually precocious girls we used Bayley-Pinneau predicted adult height (P.A.H.) to discriminate patients with 'poor' or 'good' height prognosis. Patients with evidence of impaired height prognosis (P.A.H. < -1 SDS) (Group 1) were immediately treated with LH-RH analogs, while patients with unimpaired height prognosis (P.A.H. > -1 SDS) (Group 2) were followed without therapy. Two yr of treatment significantly improved P.A.H. in Group 1 patients, from a mean of -1.68 +/- 0.4 to a mean of -0.57 +/- 0.6 (SDS) (p < 0.01). After the 2 yr observation period, Group 2 patients showed no significant variation of P.A.H. (from a mean of 0.45 +/- 0.8 to a mean of 0.33 +/- 0.6). The retrospective analysis of the growth pattern changes in the two Groups seems to indicate that LH-RH agonist treatment improves height potential in girls with initial poor height prognosis and that girls with initial good height prognosis maintain an unimpaired growth potential.
Bassi
F
F
Dipartimento di Fisiopatologia Clinica, University of Firenze, Italy.
Bartolini
O
O
Neri
A S
AS
Gheri
R G
RG
Bucciantini
S
S
Cheli
D
D
Bruni
V
V
D000367:Age Factors; D001827:Body Height / Q000187:drug effects; D001940:Breast / Q000254:growth & development; D002648:Child; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects; D011379:Prognosis; D011446:Prospective Studies; D011629:Puberty, Precocious / Q000175:diagnosis* / Q000188:drug therapy
D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone